Crystal structure of IL-36gamma complexed to A-552

Experimental Data Snapshot

  • Resolution: 2.00 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.216 
  • R-Value Observed: 0.217 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Small Molecule IL-36 gamma Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.

Todorovic, V.Su, Z.Putman, C.B.Kakavas, S.J.Salte, K.M.McDonald, H.A.Wetter, J.B.Paulsboe, S.E.Sun, Q.Gerstein, C.E.Medina, L.Sielaff, B.Sadhukhan, R.Stockmann, H.Richardson, P.L.Qiu, W.Argiriadi, M.A.Henry, R.F.Herold, J.M.Shotwell, J.B.McGaraughty, S.P.Honore, P.Gopalakrishnan, S.M.Sun, C.C.Scott, V.E.

(2019) Sci Rep 9: 9089-9089

  • DOI: https://doi.org/10.1038/s41598-019-45626-w
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    IL-36 cytokines are pro-inflammatory members of the IL-1 family that are upregulated in inflammatory disorders. Specifically, IL-36γ is highly expressed in active psoriatic lesions and can drive pro-inflammatory processes in 3D human skin equivalents supporting a role for this target in skin inflammation. Small molecule antagonists of interleukins have been historically challenging to generate. Nevertheless, we performed a small molecule high-throughput screen to identify IL-36 antagonists using a novel TR-FRET binding assay. Several compounds, including 2-oxypyrimidine containing structural analogs of the marketed endothelin receptor A antagonist Ambrisentan, were identified as hits from the screen. A-552 was identified as a the most potent antagonist of human IL-36γ, but not the closely related family member IL-36α, was capable of attenuating IL-36γ induced responses in mouse and human disease models. Additionally, x-ray crystallography studies identified key amino acid residues in the binding pocket present in human IL-36γ that are absent in human IL-36α. A-552 represents a first-in-class small molecule antagonist of IL-36 signaling that could be used as a chemical tool to further investigate the role of this pathway in inflammatory skin diseases such as psoriasis.

  • Organizational Affiliation

    AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL, 60064, USA. Victoria.E.Scott@abbvie.com.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Interleukin-36 gamma152Homo sapiensMutation(s): 0 
Gene Names: IL36GIL1EIL1F9IL1H1IL1RP2UNQ2456/PRO5737
UniProt & NIH Common Fund Data Resources
Find proteins for Q9NZH8 (Homo sapiens)
Explore Q9NZH8 
Go to UniProtKB:  Q9NZH8
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9NZH8
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
O6D (Subject of Investigation/LOI)
Query on O6D

Download Ideal Coordinates CCD File 
B [auth A](2S)-2-{[4-(3-amino-4-methylphenyl)-6-methylpyrimidin-2-yl]oxy}-3-methoxy-3,3-diphenylpropanoic acid
C28 H27 N3 O4
Binding Affinity Annotations 
IDSourceBinding Affinity
O6D Binding MOAD:  6P9E Kd: 67.6 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 2.00 Å
  • R-Value Free: 0.242 
  • R-Value Work: 0.216 
  • R-Value Observed: 0.217 
  • Space Group: I 2 3
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 96.42α = 90
b = 96.42β = 90
c = 96.42γ = 90
Software Package:
Software NamePurpose
XDSdata reduction
autoPROCdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2019-06-26
    Type: Initial release
  • Version 1.1: 2019-07-10
    Changes: Data collection, Database references
  • Version 1.2: 2023-10-11
    Changes: Data collection, Database references, Refinement description